EMERYVILLE, Calif.--(KineMed, Inc. (www.kinemed.com) announced today that Dr. Patrizia Fanara, Vice President, Neuroscience at KineMed, Inc., will present “Applying Kinetic Biomarkers to the Diagnosis and Treatment of Parkinson’s Disease and Other Neurological Disorders” at the 6th Neurodegenerative Conditions Research and Development Conference on Friday September 14th, in San Francisco, California.)--
“Is this drug right for the patient?”
Dr. Fanara will show what can be done with the KineMed platform to advance drug discovery, with examples from CNS research, illustrating how isotopic labeling can be used to study diseases and translate from pre-clinical into human studies.
The presentation will provide an overview of the Company’s proprietary biomarker platform, which uses in vivo labeling with deuterated or “heavy” water, combined with specialized mass spectrometric analysis of biomolecules important in the pathogenesis of the nervous system. Applications of this unique approach in preclinical and clinical research studies will be discussed. Specifically, the presentation will illustrate how deuterium labeling patterns of proteins driving neuronal dysfunction can be translated from tissue to body fluids between disease and healthy states.
“It is literally thrilling to be able to observe and study what happens to neurons in Parkinson’s patients,” said Dr. Fanara, “Our unique class of biomarkers track changes in mechanisms that affect the nervous system of living patients. Kinetic markers enable scientists and physicians to define the early stages of neurodegeneration and facilitate the development of successful therapies for Parkinson’s and other neurological diseases.”
The presentation will take place at 1:45 pm on Friday September 14th in the session titled “Biomarkers: Translation from Discovery to Clinical”, at the San Francisco Hilton, 750 Kearny Street, San Francisco California.
About KineMed, Inc.
KineMed, Inc., is a biomarker discovery and development company based in Emeryville, California. Our biomarkers provide predictive, actionable information to dramatically improve, de-risk and accelerate drug discovery, development and disease management decisions. The Company’s proprietary assays reveal dynamic causal processes of disease, rather than isolated molecular targets, and provide precise measures of therapeutic effectiveness on these processes. KineMed’s translational assays extract “yes/no” answers from the complexity of protein dynamics and network biology, addressing treatment questions such as “Is this drug right for the patient?” and “Is the drug working?”
KineMed’s biomarkers are fully translational from animal to man, seamlessly harmonizing data across pre-clinical and clinical phases of development, through to the diagnosis and management of diseases including fibrotic, metabolic, cardiovascular disease, and cancer.
KineMed’s platform addresses key industry needs:
- Focus on causes rather than symptoms: Generating pivotal knowledge for developing novel therapeutics that are differentiated by targeting underlying biochemical causes and mode of action
- Systems biology approach: Insight into intact living systems, rather than simplified models, ensures that drug effects are understood in their intended biological context
- Reduce late-stage attrition: Early, decision-relevant metrics of drug activity separate winners from losers and reduce later failures to improve the NPV of R&D spend
- Powerful assays of disease state: Custom-developed assays create companion diagnostic tests for personalized medicine
In addition to assisting clients, KineMed also has an active pipeline of therapeutics and diagnostics in development. KineMed is seeking further broad collaborations with biotechnology, pharmaceutical, CRO, histopathology, diagnostics and medical instrument partners.
For more information about KineMed, please visit: http://www.kinemed.com